| scholarly article | Q13442814 |
| P2093 | author name string | Levine SR | |
| Jacobs BS | |||
| P2860 | cites work | Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 |
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases | Q33408807 | ||
| Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome | Q33488745 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke | Q34462070 | ||
| A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group | Q34540010 | ||
| THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS | Q34540619 | ||
| Stroke and Parkinson's disease | Q36160367 | ||
| Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic 'rheumatic type' valvular heart disease | Q40776802 | ||
| Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options | Q41270539 | ||
| Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus | Q41837002 | ||
| European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke | Q42551725 | ||
| Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group | Q48537069 | ||
| IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. | Q50933721 | ||
| Prevention of recurrent spontaneous abortion by intravenous immunoglobulin | Q69622367 | ||
| Intravenous gammaglobulin in a hypothyroid patient with the antiphospholipid antibody syndrome | Q70654708 | ||
| Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry | Q71112355 | ||
| Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies | Q71912216 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events | Q72776648 | ||
| AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association | Q73149835 | ||
| A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group | Q73388182 | ||
| Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis | Q73867179 | ||
| Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome | Q73895637 | ||
| A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group | Q73951222 | ||
| Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies | Q73978602 | ||
| Anticardiolipin antibodies and their associations with cerebrovascular risk factors | Q77398222 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 449-458 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Current treatment options in neurology | Q26842298 |
| P1476 | title | Antiphospholipid Antibody Syndrome. | |
| P478 | volume | 2 |
| Q37473270 | Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome |
| Q36254845 | Hypercoagulable states and stroke: a selective review. |
| Q28193706 | Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome) |
| Q81153272 | [Cerebral infarction of arterial origin and haematological causation: the Lausanne experience and a review of the literature] |
Search more.